Journey Medical Corporation
Scottsdale, United States · Biotechnology, Healthcare, Health Care
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and hea
Key facts
- Headquarters
- Scottsdale, United States
- Employees
- 73
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (DERM)
- Website
- journeymedicalcorp.com
- Company page
Recent activity at Journey Medical Corporation
- : SEC 8-K (5.07): On June 24, 2026, Journey Medical Corporation held its 2026 Annual Meeting, where stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A Common Stock (totaling 81% of the shares entitled to vote) approved the election of six directors for a term until the 2027 annual meeting and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. This meeting, conducted via an online platform, showcased significant shareholder engagement given the quorum achieved.
- : SEC 8-K (8.01): On April 21, 2026, Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, which includes 40 mg Minocycline Hydrochloride Modified-Release Capsules and a combination of 10 mg immediate release and 30 mg extended release formulations. This expansion is significant as it enhances patient access to the treatment for inflammatory lesions of rosacea in adults. The filing includes a press release detailing the coverage expansion, emphasizing the company's commitment to improving health outcomes for patients requiring this treatment. This event reflects a strategic initiative to broaden the market reach and adoption of their product.
- : SEC 8-K (8.01): Journey Medical Corporation announced the expansion in pharmacy benefit coverage for its treatment Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) on April 21, 2026. This expansion is significant as it enhances patient access to the medication for the treatment of inflammatory lesions of rosacea in adults. The announcement includes a press release attached as Exhibit 99.1, detailing the implications of this coverage increase. Such a move could positively impact sales and market penetration of Emrosi™, providing a strategic advantage in the competitive pharmaceutical landscape.
- : Journey Medical Promotes Ramsey Alloush to Chief Operating Officer
- : Journey Medical Corporation announces the FDA approval of Emrosi™ for treating rosacea, providing a new option for patients in the U.S.
- : Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer
- : Journey Medical Corp
- : Journey Medical Corp
Journey Medical Corporation funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2021 | Venture | $19.0M |
| Sep 2021 | Venture | $19.0M |
Leadership
- Lindsay Rosenwald, Director
- Neil Herskowitz, Director
- Jeff Paley, Director
- Miranda Toledano, Director
- Ramsey Alloush, Chief Operating Officer
- Joseph M. Benesch, Chief Financial Officer
- Claude Maraoui, Executive Officer
- Claude Maraoui, Executive Officer
- Robyn Hunter, Executive Officer
- Justin Smith, Executive Officer
Verified email and direct lines for Journey Medical Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Journey Medical Corporation in the news
- Journey Medical Corporation to Participate in September 2026 Investor Conferences - GlobeNewswire (Sep 08, 2026)
- DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times (Jan 09, 2025)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Michael McKelvey, MD - PRLog (Jun 11, 2021)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Naiem T. Issa, MD, PhD - PRLog (Apr 12, 2024)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Alexander Doctoroff, DO - PRLog (Sep 17, 2021)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Kimberly Vincent, MD - PRLog (Nov 23, 2021)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring Rocco Serrao, MD - PRLog (Jan 14, 2022)
- Journey Medical Corp Announces New Journey with the Experts Video Featuring David Gorsulowsky, MD - PRLog (Oct 05, 2021)
Companies similar to Journey Medical Corporation
- Biofrontera · Biotechnology, Healthcare, Health Care, Pharmaceutical
- Ligand Pharmaceuticals Incorporated · Biotechnology, Healthcare, Health Care, Pharmaceutical
- ETON PHARMACEUTICALS · Biotechnology, Healthcare, Health Care, Pharmaceutical
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical
- Cingulate · Biotechnology, Healthcare, Health Care, Pharmaceutical
About Journey Medical Corporation: questions and answers
What does Journey Medical Corporation do?
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and hea
Where is Journey Medical Corporation headquartered?
Journey Medical Corporation is headquartered in Scottsdale, United States.
How many employees does Journey Medical Corporation have?
Journey Medical Corporation has about 73 employees.
Has Journey Medical Corporation raised funding?
Yes. Fundz has recorded 2 funding events for Journey Medical Corporation. The most recent, $19.0M, was in Oct 2021.
What is the latest news on Journey Medical Corporation?
On Jun 24, 2026, SEC 8-K (5.07): On June 24, 2026, Journey Medical Corporation held its 2026 Annual Meeting, where stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A Common Stock (totaling 81% of the shares entitled to vote) approved the election of six directors for a term u
Is Journey Medical Corporation a public company?
Yes. Journey Medical Corporation is publicly traded under the ticker DERM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy